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Materials and Methods: From January 2011 to December 
2013, 155 patients (97 male / 58 female) who had 
histopathologically confirmed NPC treated in our department 
with definitive-intent RT to a dose of 54 – 57 Gy (3 Gy daily 
fraction) for nasopharyngeal tumour and positive neck lymph 
nodes. The dose for the prevention irradiation of negative 
neck lymph nodes was 36 – 51 Gy (3 Gy daily fraction). 
Results: Mean age was 44.9 ± 1.1 years (Range 16-81). Stage 
I, II, III, IVA and IVB (UICC 2009) were 7, 32, 40, 51 and 25 
respectively. 118 patients received induction chemotherapy 
platinum-based. Commonest adverse effects (NCI-CTC 4.0) 
were: mucositis, dysphagia, and dermatisis. Grade 3 or 4 
mucositis, dysphagia, dermatisis occurred in 16 cases (10.3%), 
15 cases (9.7%) and 4 cases (2.6%) respectively. Response 
rate of 154 patients were (1 patient was refused evaluation): 
complete response 65.6%, Partial response 24.1%, stable 
disease 7.1% and progressive disease 3.2%. With median 
follow-up of 18 months, 10 and 15 patients were presented 
locoregional recurrence and metastasis respectively. The 
locoregional control (LRC), Metastasis free survival (MFS), 
disease free survival (DFS) and overall survival (OS) rates at 
one year were: 95.8% (±1.8%), 89.3% (±2.6%), 85.2 % (±3.1%) 
and 93.9% (±2.1%), respectively. 
Conclusions: Preliminary findings using a hypofractionated 
scheme is a feasible option in the treatment of NPC (an 
effective regimen with an acceptable safety profile). 
However, an important number of patients and a longer 
follow-up are necessary to better appreciate the efficacy and 
the toxicity outcome (late effect) of this scheme.  
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Purpose/Objective: Currently, during the delivery of the 
Rapid Arc® (RA)/Volumetric Modulated Arc Therapy (VMAT) 
plan, the jaws are fixed allowing the possibility of radiation 
leaking in-between leaves and in-between the leaves gaps 
from opposite pairs. The purpose of this work is to evaluate 
the potential improvement in Rapid Arc plans dosimetry when 
plan delivery allows for jaw tracking. This work represents 
one of the initial attempts to assess the usefulness of 
evaluating normal tissue dose reduction in dynamic VMAT on 
the True beam STx platform by tracking the multi-leaf 
collimator (MLC) apertures with the accelerator jaws. 
Materials and Methods: We use the Eclipse (version 10.4) and 
Truebeam STx linear accelerator which allows jaw tracking 
during VMAT delivery for both the X and Y jaws. We 
considered, Brain, Head & Neck patients. We set the 
collimator between 15oand 30o and generate plans with and 
without jaw tracking for comparison. Special attention is 
given to the low dose regions where more noticeable 
differences were expected.Clinical radiation treatment plans 
for Brain, Head and Neck patients were converted to plans 
with the jaws tracking. Each plan without jaw tracking were 
planned to obtain target coverage within 1% of that in the 
original jaw tracking plan. The new plans were compared to 
the original plans in a Varian Eclipse treatment planning 
system (TPS). Reduction in normal tissue dose was evaluated 
in the new plan by using the parameters V5, V10, and V20 in 
the cumulative dose-volume histogram for the following 
structures: Brainstem, Spinal cord, Parotids. Cochlea, Oral 
Cavity, Larynx, Mandible In order to validate the accuracy of 
our beam model, MLC transmission measurements were made 
and compared to those predicted by the TPS. 
Results: The greatest change between the original plan and 
new plan occurred at lower dose levels. The reduction in V20 
was never more than 3.7% and was typically less than 1% for 
all patients. The reduction in V10 was never more than 6.9% 
and was typically less than 1.5% for all patients. The 
reduction in V5 was 1.4% maximum and was typically less 
than 0.5% for all patients. The variation in normal tissue dose 
reduction was not predictable, and we found no clear 
parameters that indicated which patients would benefit most 
from jaw tracking. Our TPS model of MLC transmission agreed 
with measurements with absolute transmission differences of 
less than 0.1 % and thus uncertainties in the model did not 
contribute significantly to the uncertainty in the dose 
determination 
Conclusions: The amount of dose reduction achieved by 
collimating the jaws around each MLC aperture in VMAT 
appears to be similar and not more than 2%. Currently we are 
analysing more plans for other sites and with other 
geometries to improve the statistical significance of our 
conclusion. 
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Purpose/Objective: The aim of the work was to assess the 
significance of beta-tubulin II (βT-II) expression as a 
predictive marker for clinical response to neoadjuvant TPF 
chemotherapy (Docetaxel, Cisplatin, Fluorouracil) in locally 
advanced squamous cell head and neck cancers (LASHNC). 
Materials and Methods: A group of 31 patients, without 
distant metastasis, with LASHNC in clinical stage III or IV of 
disease, not qualified primary for concurrent chemoradiation 
because of large primary tumor or bulky neck lymph nodes 
metastases, was analyzed retrospectively. In the therapy, 2–3 
cycles of neoadjuvant TPF chemotherapy were used, 
followed by radiotherapy or chemoradiotherapy in all 
patients. The tumor response to neoadjuvant therapy was 
assessed according to RECIST vs 1.1, based on the results of 
facial skeleton CT scanning before and after the 
chemotherapy. Using immunohistochemical method, the 
presence of βT-II in the tumor tissue was assayed in paraffin-
embedded, archive tissue material collected from the 
patients before the start of the therapy. A computer analysis 
of IHC reaction image was performed using DensitoQuant 
software (3DHISTECH, Hungary). The high expression 
threshold was defined as presence of >17% of moderate and 
strong reactions in the specimen. The clinical response to 
TPF chemotherapy as categorized according to RECIST and by 
percentage of measurable lesions regression, in the context 
of level of βT-II in cancer cells was analyzed. 
Results: 12 specimens (38.7%) were classified to high and 19 
specimens (61.3%) to low protein expression group. Partial 
regression (PR) of lesions after neoadjuvant chemotherapy 
